piperaquine

Also Known As:

1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane; piperaquine phosphate; piperaquine phosphate (1:1); piperaquine phosphate (1:4) anhydrous; piperaquine tetraphosphate anhydrous; piperaquine tetraphosphate tetrahydrate; quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-); quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-, phosphate (1:1); quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-, phosphate (1:4); quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-, phosphate, hydrate (1:4:4)

Networked: 512 relevant articles (135 outcomes, 150 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - piperaquine: 512
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 148
      - piperaquine: 512

Experts

1.	White, Nicholas J: 50 articles (05/2024 - 01/2004)
2.	Dorsey, Grant: 46 articles (04/2024 - 05/2007)
3.	Tarning, Joel: 36 articles (04/2024 - 07/2010)
4.	Kamya, Moses R: 35 articles (04/2024 - 05/2007)
5.	Kakuru, Abel: 32 articles (04/2024 - 11/2009)
6.	Rosenthal, Philip J: 29 articles (01/2023 - 05/2007)
7.	D'Alessandro, Umberto: 25 articles (02/2024 - 12/2006)
8.	Nosten, François: 23 articles (01/2023 - 05/2007)
9.	Ter Kuile, Feiko O: 22 articles (01/2024 - 03/2013)
10.	Jagannathan, Prasanna: 19 articles (04/2024 - 04/2013)

Related Diseases

1.	Malaria 05/02/2024 - "Despite the positive results in fighting malaria, inhibition of the Kv11.1 channel (hERG; encoded by the KCNH2 gene) by piperaquine has raised concerns about cardiac safety. " 01/01/2018 - "The contribution of the two PQ metabolites to the efficacy of piperaquine as a partner drug of ACT for the treatment of malaria should be considered for PQ dose optimization." 05/16/2024 - "Whether and how malaria alters the disposition of piperaquine (PQ) was investigated in this study. " 01/01/2018 - "In a two-step (parallel-group) pharmacokinetic trial with intensive blood sampling, we compared the area under the concentration-time curve from days 0 to 28 (AUC0-28 days) and the safety outcomes of piperaquine among malaria-uninfected HIV+ adults. " 09/28/2009 - "The long terminal half life of piperaquine makes it suitable for intermittent preventive treatment for malaria but no studies of its use for prevention have been done in Africa. "
2.	Falciparum Malaria (Plasmodium falciparum Malaria) 11/15/2004 - "The current dosage of DP (6.4 mg/kg DHA and 51.2 mg/kg piperaquine phosphate) given over the course of 48 h is highly effective, safe, and well tolerated for the treatment of multidrug-resistant falciparum malaria, and its efficacy is not improved by the addition of more DHA." 11/01/2012 - "Piperaquine (PQ) is part of a first-line treatment regimen for Plasmodium falciparum malaria recommended by the World Health Organization (WHO). " 11/29/2012 - "The aim of this study was to investigate the population pharmacokinetics of piperaquine in pregnant and non-pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria. " 03/01/2012 - "The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso. " 09/01/2011 - "This pharmacokinetic study monitored 30 adult patients with uncomplicated falciparum malaria for 4.5 months to evaluate the effects of the concomitant intake of fat on the total piperaquine exposure. "
3.	Infections 01/01/2019 - "Our models predict that higher piperaquine concentrations are needed to prevent infections with the pfmdr1/pfcrt mutant compared to those with wild-type parasites and that, despite selection for mutants by DHA-PQ, the overall burden of mutant infections is lower for IPTp with DHA-PQ than for IPTp with SP. (This study has been registered at ClinicalTrials.gov under identifier NCT02282293.)." 03/01/2016 - "Patients with recrudescent P falciparum infections were more likely to have detectable piperaquine plasma concentrations at baseline compared with non-recrudescent patients, but did not differ significantly in age, initial parasite density, or piperaquine plasma concentrations at 7 days. " 06/01/2015 - "This combination triple mutation was associated with a 5·4 times greater risk of treatment failure (hazard ratio 5·4 [95% CI 2·4-12]; p<0·0001) and higher piperaquine 50% inhibitory concentration (triple mutant 34 nM [28-41]; non-triple mutant 24 nM [1-27]; p=0·003) than other infections had. " 08/01/2011 - "The pharmacokinetic mismatching of these drugs, whose plasma half-lives are ~20 days and ~1 h, respectively, implies that recrudescent or new infections emerging shortly after treatment cessation will encounter piperaquine as a monotherapy agent. " 07/01/2016 - "Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia."
4.	Vivax Malaria 08/27/2014 - "vivax malaria was accommodated by a constant baseline hazard (8.94 relapses/year) with the addition of a surge function in a fixed 3-week interval and a protective piperaquine effect. " 03/01/2004 - "Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria." 11/27/2022 - "Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia." 01/01/2013 - "This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine (DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries. " 01/01/2013 - "Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies."
5.	Parasitemia 01/01/2023 - "Piperaquine was administered on days 9 and 11 to clear asexual parasitemia while allowing gametocyte development. " 01/01/2019 - "An increase in the piperaquine plasma concentration was associated with a log-linear decrease in risk of parasitemia. " 01/01/2019 - "Understanding the relationships between piperaquine concentration, prevention of parasitemia, and selection for decreased drug sensitivity can inform control policies and optimization of DHA-PQ dosing. " 04/01/2017 - "A further wave of commitment is observed following recrudescent asexual parasitemia, and these gametocytes are again refractory to piperaquine treatment. " 01/01/1989 - "At 14-28d follow-up recrudescence was observed with asexual parasitemia in 7 of the 47 cases, showing RI resistance to piperaquine. "

Related Drugs and Biologics

1.	artenimol (dihydroartemisinin)
2.	Lumefantrine Drug Combination Artemether (Coartem)
3.	artemisinin (artemisinine)
4.	Artesunate
5.	Amodiaquine (Camoquin)
6.	Antimalarials (Antimalarial Agents)
7.	pyrimethamine drug combination fanasil (Fansidar)
8.	Mefloquine (Lariam)
9.	Chloroquine (Aralen)
10.	Primaquine

Related Therapies and Procedures

1.	Therapeutics
2.	Chemoprevention
3.	Mass Drug Administration
4.	Aftercare (After-Treatment)
5.	Prenatal Care (Care, Prenatal)